Torrent Pharmaceuticals Ltd (TORNTPHARM) — shareholding pattern, promoter holding, financials and share price
About Torrent Pharmaceuticals Ltd (TORNTPHARM)
Torrent Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as TORNTPHARM and on the BSE under scrip code 500420. Its ISIN is INE685A01028.
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. [1] It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses. [2]
Torrent Pharmaceuticals is an India‑headquartered, vertically integrated pharmaceutical company focused on branded chronic and sub‑chronic therapies, with a diversified international presence across the US, Europe (Germany) and Latin America (Brazil) and over 15 country subsidiaries supporting formulation manufacturing, R&D and commercial operations for both regulated and emerging markets.
In Q3 FY26 Torrent reported consolidated revenues of INR 3,303 crore, up 18% year‑on‑year, with Operating EBITDA of INR 1,088 crore and an operating margin of 32.9%. Branded markets contributed roughly 75% of revenues; India grew 14% and Brazil grew 27%, while the U.S. and Germany contributed double‑digit and modest growth respectively amid some supply constraints.
Listed peers in Pharmaceuticals: Divis Laboratories Ltd, Cipla Ltd, Zydus Lifesciences Ltd, Lupin Ltd, Mankind Pharma Ltd, Dr Reddys Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹4,895.2 a share on 10 Jul 2026, Torrent Pharmaceuticals Ltd (TORNTPHARM) was valued at a price-to-earnings ratio of 87.09x against an industry P/E of 36.41x and a price-to-book of 22.2x on a book value of ₹220.53 per share as of Mar 2026. Solomo computes return on equity of 25.49% and return on capital employed of 13.91% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 87.09x
- Industry P/E
- 36.41x
- P/B
- 22.2x
- EPS (TTM)
- ₹56.21
- Book value / share
- ₹220.53
- ROE
- 25.49%
- ROCE
- 13.91%
- ROA
- 4.82%
- Debt / equity
- 1.79x
- Dividend yield
- 0.78%
- EBITDA margin
- 31.82%
- 52-week range
- ₹3,307.1 – ₹4,948.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Torrent Pharmaceuticals Ltd (TORNTPHARM) reported revenue of ₹13,980 crore, net profit of ₹2,138 crore and earnings per share of ₹63.92. That compares with revenue of ₹11,516 crore and net profit of ₹1,911 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹4,197 crore and net profit ₹364 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 8,508 | 9,620 | 10,728 | 11,516 | 13,980 |
| Net profit (₹ cr) | 777 | 1,245 | 1,656 | 1,911 | 2,138 |
| EPS (₹) | 22.97 | 36.79 | 48.94 | 56.47 | 63.92 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 9.87% | 10.68% | 11.66% | 67.37% |
| Profit growth | 11.04% | 14.01% | 27.74% | 11.87% |
| Stock price CAGR | 22% | 27% | 37% | 44% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 68.31% of Torrent Pharmaceuticals Ltd (TORNTPHARM) (unchanged from the previous quarter), foreign institutional investors (FII) hold 15.44% and domestic institutional investors (DII) hold 9.83%. Market capitalisation was ₹1,86,198 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: NPS TRUST 2.5%, HDFC LARGE AND MID CAP FUND 1.15%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 68.31% | - | 15.44% | 9.83% | 31.69% |
| Mar 2026 | 68.31% | - | 16.18% | 9.06% | 31.69% |
| Dec 2025 | 68.31% | - | 16.13% | 9.14% | 31.69% |
| Sep 2025 | 68.31% | - | 15.92% | 9.28% | 31.69% |
| Jun 2025 | 68.31% | - | 16.09% | 8.65% | 31.69% |
| Mar 2025 | 68.31% | - | 16.31% | 8.35% | 31.69% |
| Dec 2024 | 68.31% | - | 16.17% | 8.35% | 31.69% |
| Sep 2024 | 71.25% | - | 14.46% | 7.08% | 28.75% |